costeffectiveness of renal denervation therapy for the treatment of resistant hypertension in the netherlands objectives safety and efficacy data for catheterbased renal denervation rdn in the treatment of resistant hypertension have been used to estimate the costeffectiveness of this approach however there are no dutchspecific analyses this study examined the costeffectiveness of rdn from the perspective of the healthcare payer in the netherlandsmethods a previously constructed markov statetransition model was adapted and updated with costs and utilities relevant to the dutch setting the costeffectiveness of rdn was compared with standard of care soc for patients with resistant hypertension the efficacy of rdn treatment was modeled as a reduction in the risk of cardiovascular events associated with a lower systolic blood pressure sbpresults treatment with rdn compared to soc gave an incremental qualityadjusted life year qaly gain of 089 at an additional cost of 1315 over a patients lifetime resulting in a base case incremental costeffectiveness ratio icer of 1474 deterministic and probabilistic sensitivity analyses psa showed that treatment with rdn therapy was costeffective at conventional willingnesstopay thresholds 1000080000qalyconclusion rdn is a costeffective intervention for patients with resistant hypertension in the netherlands